ESTIMATED
04/02/2024
04/02/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.45 | -$0.45 | -$0.45 |
Q2 2024 | 0 | -$0.45 | -$0.45 | -$0.45 |
Q3 2024 | 0 | -$0.45 | -$0.45 | -$0.45 |
Q4 2024 | 0 | -$0.45 | -$0.45 | -$0.45 |
Q1 2025 | 0 | -$0.64 | -$0.64 | -$0.64 |
Q2 2025 | 0 | -$0.53 | -$0.53 | -$0.53 |
Q3 2025 | 0 | -$0.49 | -$0.49 | -$0.49 |
Q4 2025 | 0 | -$0.37 | -$0.37 | -$0.37 |
Alaunos Therapeutics, Inc. last posted its earnings results on Tuesday, April 2nd, 2024. The company reported $-0.6 earnings per share for the quarter, missing analysts' consensus estimates of $-0.6 by $0. The company had revenue of 1,000 for the quarter and had revenue of 5,000 for the year. Alaunos Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-2.2 diluted earnings per share) and currently has a price-to-earnings ratio of -0.39. Alaunos Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/15/2024 | Q1 2024 | -$0.11 | $1,000 | $1,000 | 04/01/2024 | Q4 2023 | -$0.49 | $1,000 | $1,000 | 09/29/2023 | Q3 2023 | -$0.53 | $0 | 08/14/2023 | Q2 2023 | -$0.60 | -$0.55 | 0.05 | $4,000 | 05/10/2023 | Q1 2023 | -$0.60 | -$0.59 | 0.01 | $0 | 03/07/2023 | Q4 2022 | -$1.35 | -$0.66 | 0.69 | $11,000 | 11/14/2022 | Q3 2022 | -$1.80 | -$0.04 | 1.76 | $2.91 M | 08/15/2022 | Q2 2022 | -$1.65 | -$0.05 | 1.6 | $0 | 05/16/2022 | Q1 2022 | -$1.35 | -$0.05 | 1.3 | $0 | 03/30/2022 | Q4 2021 | -$1.35 | -$0.05 | 1.3 | $0 | 11/08/2021 | Q3 2021 | -$0.13 | -$0.11 | 0.02 | $398,000 | 08/13/2021 | Q2 2021 | -$0.12 | -$0.11 | 0.01 | $0 | 05/06/2021 | Q1 2021 | -$0.10 | -$0.10 | 0 | $0 | 03/01/2021 | Q4 2020 | -$0.11 | $0 | 11/05/2020 | Q3 2020 | -$0.09 | -$0.10 | -0.01 | $0 | 08/06/2020 | Q2 2020 | -$0.09 | -$0.09 | 0 | $0 | 05/07/2020 | Q1 2020 | -$0.08 | -$0.09 | -0.01 | $0 | 03/02/2020 | Q4 2019 | -$0.08 | -$0.09 | -0.01 | $0 | 11/07/2019 | Q3 2019 | -$0.09 | -$0.43 | -0.34 | $400,000 | $0 | 08/08/2019 | Q2 2019 | -$0.08 | -$0.09 | -0.01 | $2.45 M | $0 |
---|
A. Alaunos Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off last year's report dates.
A. The conference call for Alaunos Therapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Alaunos Therapeutics, Inc.'s latest earnings report can be read online.
A. Alaunos Therapeutics, Inc. (NASDAQ:TCRT) has a recorded annual revenue of $5,000.
A. Alaunos Therapeutics, Inc. (NASDAQ:TCRT) has a recorded net income of $5,000. Alaunos Therapeutics, Inc. has generated $-2.2 earnings per share over the last four quarters.
A. Alaunos Therapeutics, Inc. (NASDAQ:TCRT) has a price-to-earnings ratio of -0.39 and price/earnings-to-growth ratio is -9.09.